Details of the Drug

General Information of Drug (ID: DMMGAUK)

• Drug Name: AGN-XX/YY
• Synonyms: Rezatomidine

Indication

Disease Entry	ICD 11	Status	REF
Diabetic nephropathy	GB61.Z	Phase 2	[1]
Fibromyalgia	MG30.01	Phase 2	[1]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 232.35
  Logarithm of the Partition Coefficient (xlogp); 2.7
  Rotatable Bond Count (rotbonds); 2
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 1
• Chemical Identifiers:
  Formula: C13H16N2S
  IUPAC Name: 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1,3-dihydroimidazole-2-thione
  Canonical SMILES: CC1=C(C(=CC=C1)[C@H](C)C2=CNC(=S)N2)C
  InChI: InChI=1S/C13H16N2S/c1-8-5-4-6-11(9(8)2)10(3)12-7-14-13(16)15-12/h4-7,10H,1-3H3,(H2,14,15,16)/t10-/m0/s1
  InChIKey: WQXVKEDUCPMRRI-JTQLQIEISA-N
• Cross-matching ID:
  PubChem CID: 11287722
  CAS Number: 847829-38-3
  DrugBank ID: DB12143
  TTD ID: D00BWF
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor alpha-2C (ADRA2C)	TT2NUT5	ADA2C_HUMAN	Agonist	[2]

Molecular Expression Atlas of This Drug

• The Studied Disease: Diabetic nephropathy
• ICD Disease Classification: GB61.Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Adrenergic receptor alpha-2C (ADRA2C)	DTT	ADRA2C	1.76E-01	-0.06	-0.28

References

• [1] Clinical pipeline report, company report or official report of ACADIA Pharmaceuticals.
• [2] Patent WO2008058220 A2.